Gina Keiffer1, Neil Palmisiano2. 1. Thomas Jefferson University Hospital, 834 Chestnut St, Suite 315, Philadelphia, PA, 19107, USA. gina.keiffer@jefferson.edu. 2. Thomas Jefferson University Hospital, 834 Chestnut St, Suite 315, Philadelphia, PA, 19107, USA.
Abstract
PURPOSE OF REVIEW: Acute myeloid leukemia (AML) disproportionately impacts elderly patients. Treating elderly patients with AML has been a challenge due to the increased prevalence of medical comorbidities and decreased performance status in this population, as well as the different biology of AML in elderly patients. RECENT FINDINGS: The care of elderly patients with AML has advanced significantly over the past few years. Our greater understanding of the biology of AML in elderly patients has led to the development of novel, lower-intensity treatment options. We present here a review of the most recent literature regarding therapeutic options available to older patients, as well as tools to help identify the right treatment for the right patient. As targeted and lower-intensity treatment options become available, developing an approach to "right size" therapy for individual elderly patients is paramount.
PURPOSE OF REVIEW: Acute myeloid leukemia (AML) disproportionately impacts elderly patients. Treating elderly patients with AML has been a challenge due to the increased prevalence of medical comorbidities and decreased performance status in this population, as well as the different biology of AML in elderly patients. RECENT FINDINGS: The care of elderly patients with AML has advanced significantly over the past few years. Our greater understanding of the biology of AML in elderly patients has led to the development of novel, lower-intensity treatment options. We present here a review of the most recent literature regarding therapeutic options available to older patients, as well as tools to help identify the right treatment for the right patient. As targeted and lower-intensity treatment options become available, developing an approach to "right size" therapy for individual elderly patients is paramount.
Authors: Frederick R Appelbaum; Holly Gundacker; David R Head; Marilyn L Slovak; Cheryl L Willman; John E Godwin; Jeanne E Anderson; Stephen H Petersdorf Journal: Blood Date: 2006-02-02 Impact factor: 22.113
Authors: S Amadori; S Suciu; R Stasi; R Willemze; F Mandelli; D Selleslag; C Denzlinger; P Muus; R Stauder; Z Berneman; J Pruijt; F Nobile; V Cassibba; J-P Marie; F Beeldens; L Baila; M Vignetti; T de Witte Journal: Leukemia Date: 2005-10 Impact factor: 11.528
Authors: Bob Löwenberg; Gert J Ossenkoppele; Wim van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Johan Maertens; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Marinus van Marwijk Kooy; Leo F Verdonck; Joachim Beck; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gregor Verhoef Journal: N Engl J Med Date: 2009-09-24 Impact factor: 91.245
Authors: Dimitri A Breems; Wim L J Van Putten; Georgine E De Greef; Shama L Van Zelderen-Bhola; Klasien B J Gerssen-Schoorl; Clemens H M Mellink; Aggie Nieuwint; Martine Jotterand; Anne Hagemeijer; H Berna Beverloo; Bob Löwenberg Journal: J Clin Oncol Date: 2008-08-11 Impact factor: 44.544
Authors: Chadi Nabhan; Lynn M Rundhaugen; Mary B Riley; Alfred Rademaker; Larry Boehlke; Mashal Jatoi; Martin S Tallman Journal: Leuk Res Date: 2005-01 Impact factor: 3.156
Authors: Gunnar Juliusson; Petar Antunovic; Asa Derolf; Sören Lehmann; Lars Möllgård; Dick Stockelberg; Ulf Tidefelt; Anders Wahlin; Martin Höglund Journal: Blood Date: 2008-11-13 Impact factor: 22.113
Authors: Alan K Burnett; Donald Milligan; Archie G Prentice; Anthony H Goldstone; Mary F McMullin; Robert K Hills; Keith Wheatley Journal: Cancer Date: 2007-03-15 Impact factor: 6.860
Authors: Fatih M Uckun; Christopher R Cogle; Tara L Lin; Sanjive Qazi; Vuong N Trieu; Gary Schiller; Justin M Watts Journal: Cancers (Basel) Date: 2019-12-26 Impact factor: 6.639